ATE542813T1 - 6-substituierte 2- heterocyclylaminopyrazinverbindungen als chk-1- inhibitoren - Google Patents

6-substituierte 2- heterocyclylaminopyrazinverbindungen als chk-1- inhibitoren

Info

Publication number
ATE542813T1
ATE542813T1 AT09786799T AT09786799T ATE542813T1 AT E542813 T1 ATE542813 T1 AT E542813T1 AT 09786799 T AT09786799 T AT 09786799T AT 09786799 T AT09786799 T AT 09786799T AT E542813 T1 ATE542813 T1 AT E542813T1
Authority
AT
Austria
Prior art keywords
chk
inhibitors
compounds
heterocyclylaminopyrazine
substituted
Prior art date
Application number
AT09786799T
Other languages
English (en)
Inventor
Sacha Ninkovic
John Frederick Braganza
Michael Raymond Collins
John Charles Kath
Hui Li
Daniel Tyler Richter
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of ATE542813T1 publication Critical patent/ATE542813T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT09786799T 2008-08-06 2009-08-04 6-substituierte 2- heterocyclylaminopyrazinverbindungen als chk-1- inhibitoren ATE542813T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8673208P 2008-08-06 2008-08-06
US22942809P 2009-07-29 2009-07-29
PCT/IB2009/053389 WO2010016005A1 (en) 2008-08-06 2009-08-04 6 substituted 2-heterocyclylamino pyrazine compounds as chk-1 inhibitors

Publications (1)

Publication Number Publication Date
ATE542813T1 true ATE542813T1 (de) 2012-02-15

Family

ID=41171261

Family Applications (1)

Application Number Title Priority Date Filing Date
AT09786799T ATE542813T1 (de) 2008-08-06 2009-08-04 6-substituierte 2- heterocyclylaminopyrazinverbindungen als chk-1- inhibitoren

Country Status (7)

Country Link
US (1) US8518952B2 (de)
EP (1) EP2328890B1 (de)
JP (1) JP5576370B2 (de)
AT (1) ATE542813T1 (de)
CA (1) CA2731368C (de)
ES (1) ES2378513T3 (de)
WO (1) WO2010016005A1 (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2921576T3 (es) 2008-12-19 2022-08-29 Vertex Pharma Compuestos útiles como inhibidores de la quinasa ATR
JP2012521354A (ja) * 2009-03-20 2012-09-13 アムジエン・インコーポレーテツド Ｐｉ３キナーゼの阻害薬
KR101774035B1 (ko) 2009-10-30 2017-09-01 얀센 파마슈티카 엔.브이. 이미다조［１，２―ｂ］피리다진 유도체 및 ＰＤＥ１０ 저해제로서의 그의 용도
EP2338888A1 (de) 2009-12-24 2011-06-29 Almirall, S.A. Imidazopyridin-Derivate als JAK-Inhibitoren
UY33213A (es) 2010-02-18 2011-09-30 Almirall Sa Derivados de pirazol como inhibidores de jak
EP2360158A1 (de) * 2010-02-18 2011-08-24 Almirall, S.A. Pyrazolderivate als JAK-Inhibitoren
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
US9334244B2 (en) 2010-05-12 2016-05-10 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
NZ603477A (en) 2010-05-12 2014-09-26 Vertex Pharma Compounds useful as inhibitors of atr kinase
EP2463289A1 (de) 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]Pyridazin-Derivate als AS JAK-Hemmer
WO2013000924A1 (en) 2011-06-27 2013-01-03 Janssen Pharmaceutica Nv 1-ARYL-4-METHYL-[1,2,4]TRIAZOLO[4,3-a]QUINOXALINE DERIVATIVES
EP2554544A1 (de) 2011-08-01 2013-02-06 Almirall, S.A. Pyridin-2(1H-)-on-Derivate als JAK-Inhibitoren
CN108685922A (zh) 2011-09-30 2018-10-23 沃泰克斯药物股份有限公司 用atr抑制剂治疗胰腺癌和非小细胞肺癌
CN106496173A (zh) 2011-09-30 2017-03-15 沃泰克斯药物股份有限公司 用于制备可用作atr激酶抑制剂的化合物的方法
US9221809B2 (en) 2011-10-31 2015-12-29 Merck Sharp & Dohme Corp. Aminopyrimidinones as interleukin receptor-associated kinase inhibitors
CN108478577A (zh) 2012-04-05 2018-09-04 沃泰克斯药物股份有限公司 可用作atr激酶抑制剂的化合物及其组合疗法
WO2014001314A1 (en) 2012-06-26 2014-01-03 Janssen Pharmaceutica Nv Combinations comprising pde 2 inhibitors such as 1-aryl-4-methyl- [1,2,4] triazolo [4,3-a] quinoxaline compounds and pde 10 inhibitors for use in the treatment of neurological or metabolic disorders
AU2013289284B2 (en) 2012-07-09 2017-03-30 Janssen Pharmaceutica Nv Inhibitors of phosphodiesterase 10 enzyme
DK2904406T3 (en) 2012-10-04 2018-06-18 Vertex Pharma METHOD OF DETERMINING THE ATR INHIBITION, INCREASED DNA DAMAGE
NZ746607A (en) 2012-11-21 2019-11-29 Ptc Therapeutics Inc Substituted reverse pyrimidine bmi-1 inhibitors
CN103254121B (zh) * 2013-04-08 2015-08-26 洛阳师范学院 一种合成(3r,4r)-n-pg-4-甲基-3-甲胺基哌啶的方法
WO2015076800A1 (en) 2013-11-21 2015-05-28 Ptc Therapeutics, Inc. Substituted pyridine and pyrazine bmi-1 inhibitors
SI3077395T1 (en) 2013-12-05 2018-03-30 Pfizer Inc. Pyrrolo(2,3-d)pyrimidinyl, pyrrolo(2,3-b)pyrazinyl and pyrrolo(2,3-d)pyridinyl acrylamides
US9145393B2 (en) * 2014-01-24 2015-09-29 Confluence Life Sciences, Inc. Arylpyridinone ITK inhibitors for treating inflammation and cancer
US9758518B2 (en) 2015-03-04 2017-09-12 Pimera, Inc. Compositions, uses and methods for making them
TR201809990T4 (en) 2014-05-09 2018-08-27 Pimera Inc NEW COMPOSITIONS, USES AND METHODS FOR THEIR MAKING.
EP3247353A4 (de) 2015-01-23 2018-07-04 Confluence Life Sciences, Inc. Heterocyclische itk-inhibitoren zur behandlung von entzündungen und krebs
EP3288943B1 (de) 2015-05-01 2022-09-28 Pfizer Inc. Pyrrolo[2,3-b]pyrazinyl acrylamide und epoxide davon als hemmstoffe von janus kinase
CN105130991B (zh) * 2015-07-10 2017-09-19 成都知普莱生物医药科技有限公司 一种合成骨形态发生蛋白受体抑制剂的方法
AU2016331955B2 (en) 2015-09-30 2022-07-21 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
CN109071546B (zh) 2016-02-24 2021-03-02 辉瑞大药厂 作为jak抑制剂的吡唑并[1,5-a]吡嗪-4-基衍生物
US10316038B2 (en) 2017-01-25 2019-06-11 Aclaris Therapeutics, Inc. Pyrrolopyrimidine ITK inhibitors for treating inflammation and cancer
EP3601286A4 (de) 2017-03-28 2020-09-23 Pimera, Inc. Neue kristalline formen eines pol1-inhibitors
CN107056681B (zh) * 2017-03-30 2019-10-01 广州白云山光华制药股份有限公司 一种托法替布中间体的制备方法
WO2019034973A1 (en) 2017-08-14 2019-02-21 Pfizer Inc. PYRAZOLO [1,5-A] PYRAZIN-4-YL AND RELATED DERIVATIVES
CN107474047B (zh) * 2017-08-29 2019-10-29 浙江工业大学 1,2,4-三唑并杂环类化合物的合成方法
CN107827811B (zh) * 2017-11-15 2021-01-29 上海皓伯化工科技有限公司 一种制备n-取代-1,2,3,6-四氢吡啶的方法
JP2021151955A (ja) * 2018-05-22 2021-09-30 株式会社カネカ 光学活性−ｃｉｓ−アミノピペリジンの製造方法
CN112839648B (zh) * 2018-06-07 2025-04-04 达萨玛治疗公司 Sarm1抑制剂
EP3608326A1 (de) 2018-08-10 2020-02-12 Irbm S.P.A. Tricyclische inhibitoren des hepatitis-c-virus
EP3836932A2 (de) 2018-08-17 2021-06-23 PTC Therapeutics, Inc. Verfahren zur behandlung von bauchspeicheldrüsenkrebs
EP3825318A1 (de) 2019-11-25 2021-05-26 Promidis S.r.l. Oxalamidosubstituierte tricyclische inhibitoren des hepatitis-b-virus
UY38705A (es) 2019-05-23 2020-12-31 Irbm S P A Inhibidores tricíclicos sustituidos con oxalamido del virus de hepatitis b
EP3741762A1 (de) 2019-05-23 2020-11-25 Irbm S.P.A. Oxalamidosubstituierte tricyclische inhibitoren des hepatitis-b-virus
IL298941A (en) 2020-06-11 2023-02-01 Chdi Foundation Inc Heterocyclic compounds and imaging agents for the imaging of huntingtin protein
JP2023538242A (ja) * 2020-07-31 2023-09-07 チルドレンズ ホスピタル メディカル センター 多環式ｉｒａｋ及びｆｌｔ３阻害化合物、並びにその使用
KR102473645B1 (ko) * 2020-08-28 2022-12-05 (주)부흥산업사 (2S,5R)-벤질 5-(t-부톡시카르보닐아미노)-2-메틸피페리딘-1-카르복실레이트의 제조방법
IL310425A (en) * 2021-07-30 2024-03-01 Childrens Hospital Med Ct Multi-cyclic irak and flt3 inhibiting compounds and uses thereof
CA3258667A1 (en) * 2022-06-10 2023-12-14 Interline Therapeutics Inc. IMIDAZO(1,2-A)PYRIDINE DERIVATIVES USED AS RIPK2 INHIBITORS
AR129535A1 (es) 2022-06-21 2024-09-04 Syngenta Crop Protection Ag Derivados de carboxamida heterocíclicos bicíclicos microbiocidas
CN120476119A (zh) 2022-10-27 2025-08-12 先正达农作物保护股份公司 杀微生物的杂双环二氢噁二嗪衍生物
CN116478076A (zh) * 2023-04-26 2023-07-25 南京优氟医药科技有限公司 一种(2s,4s)-1-叔丁氧羰基-2-(二氟甲基)-4-羟基吡咯烷的制备方法
WO2026006247A1 (en) * 2024-06-26 2026-01-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 2-(piperidin-3-yl)isoindole-1,3-dione analogs and uses thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035296A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Improved release of medicament active agents from a chewing gum coating
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
GB9722320D0 (en) 1997-10-22 1997-12-17 Janssen Pharmaceutica Nv Human cell cycle checkpoint proteins
US6383744B1 (en) 1998-07-10 2002-05-07 Incyte Genomics, Inc. Human checkpoint kinase
EP1135135A4 (de) 1998-09-18 2006-08-09 Smithkline Beecham Corp Chk1 kinase inhibitoren
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
ATE388226T1 (de) 1999-08-27 2008-03-15 Novartis Vaccines & Diagnostic Chimerische antisense-oligonukleotide und zelltransfektions-zusammensetzungen davon
WO2001021771A2 (en) 1999-09-22 2001-03-29 Canbas Co., Ltd. Compositions and methods for inhibiting g2 cell cycle arrest and sensitizing cells to dna damaging agents
US6211164B1 (en) 2000-03-10 2001-04-03 Abbott Laboratories Antisense oligonucleotides of the human chk1 gene and uses thereof
ME00502B (me) 2001-01-05 2011-10-10 Amgen Fremont Inc Antitjela za insulinu sličan receptor faktora i rasta
UA76977C2 (en) 2001-03-02 2006-10-16 Icos Corp Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US7704995B2 (en) 2002-05-03 2010-04-27 Exelixis, Inc. Protein kinase modulators and methods of use
EP1501514B1 (de) * 2002-05-03 2012-12-19 Exelixis, Inc. Proteinkinasemodulatoren und verfahren zur derer anwendung
JP3990718B2 (ja) 2003-01-09 2007-10-17 ファイザー・インク キナーゼ阻害剤としてのジアゼピノインドール誘導体
EP1641780B1 (de) 2003-06-24 2008-11-12 Pfizer Products Incorporated Verfahren zur herstellung von 1-[(benzimidazol-1-yl)chinolin-8-yl]piperidin-4-ylaminderivaten
WO2008024974A1 (en) * 2006-08-24 2008-02-28 Serenex, Inc. Pyrimidine and pyrazine derivatives
EP2211620B1 (de) 2007-10-25 2013-12-25 Merck Sharp & Dohme Corp. 3-PYRAZIN SUBSTITUIERTE PYRROLO[2,3-b]PYRIDINE ALS JANUS KINASE HEMMSTOFFE ZUR BEHANDLUNG VON KREBSERKRANKUNGEN

Also Published As

Publication number Publication date
JP5576370B2 (ja) 2014-08-20
CA2731368A1 (en) 2010-02-11
CA2731368C (en) 2013-05-14
WO2010016005A1 (en) 2010-02-11
US8518952B2 (en) 2013-08-27
EP2328890A1 (de) 2011-06-08
US20110144084A1 (en) 2011-06-16
EP2328890B1 (de) 2012-01-25
JP2011530500A (ja) 2011-12-22
ES2378513T3 (es) 2012-04-13

Similar Documents

Publication Publication Date Title
ATE542813T1 (de) 6-substituierte 2- heterocyclylaminopyrazinverbindungen als chk-1- inhibitoren
EA201000113A1 (ru) Пиразольные соединения
MY160454A (en) Oxazole substituted indazoles as pi3-kinase inhibitors
ATE552255T1 (de) 4-aminoindazole
EA201200049A1 (ru) 1,3-дизамещенные производные имидазолидин-2-она в качестве ингибиторов cyp 17
MD4582B1 (ro) Derivaţi ai 1-fenil-1H-benzimidazolului ca inhibitori ai protein kinazei
EA201100503A1 (ru) Глюкозидные производные и их применения
UA114611C2 (uk) Пестицидні композиції і способи, що їх стосуються
EA200970207A1 (ru) Соединения пиридо[2,3-d]пиримидинона и их применение в качестве pi3 ингибиторов
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
MX2013005826A (es) Benzoxazepinas como inhibidores de fosfatidilinositol 3-cinasa/objetivo de rapamicina en mamiferos (p13k/mtor) y metodos de uso y fabricacion.
EA201100580A1 (ru) Имидазопиридазинкарбонитрилы, используемые в качестве ингибиторов киназы
EA201290183A1 (ru) Бензодиазепиновый ингибитор бромодомена
MA38050B1 (fr) Inhibiteurs de gdf-8
UA108743C2 (uk) Похідні хіназолін-4(3н)-ону для застосування як інгібіторів рі3-кінази
UA107784C2 (en) Inhibitor of melanin production
EA201391239A1 (ru) Пирроло[2,3-d]пиримидиновые производные в качестве ингибиторов тропомиозин-связанных киназ
GEP20227397B (en) Inhibitors of influenza viruses replication
PE20120495A1 (es) 3-ciclopentilamino-2,2-difluor-propanoato de etilo como intermediario en la preparacion de pirimidodiazepinas
MX2011013884A (es) Sulfonamidas heterociclicas, usos y composiciones farmaceuticas de las mismas.
UA109667C2 (xx) Похідні хіназолін-4(3h)-ону, що використовуються як інгібітори pi3-кінази
NI201000059A (es) Inhibidores de la cinasa c-fms.
EA201490912A1 (ru) Производные [1,2,3]триазоло[4,5-d]пиримидина в качестве агонистов каннабиноидного рецептора 2
EA201071329A1 (ru) Диамидные производные адамантана и их применение
EA201291217A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ПРОИЗВОДНЫЕ 1-(β-D-ГЛЮКОПИРАНОЗИЛ)-2-ТИЕНИЛМЕТИЛБЕНЗОЛА КАК ИНГИБИТОРЫ НЗПГ